StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report published on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 2.2 %
TTNP stock opened at $3.30 on Friday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The firm’s fifty day simple moving average is $3.71 and its 200-day simple moving average is $4.91.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- What is the Dogs of the Dow Strategy? Overview and Examples
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Why Are Stock Sectors Important to Successful Investing?
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
